What were the results of the OASIS-5 trial regarding fondaparinux and enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention?
The OASIS-5 trial demonstrated that fondaparinux was more effective than enoxaparin in reducing the primary composite outcome of death, myocardial infarction, and refractory ischemia at 48 hours in patients with acute coronary syndromes undergoing percutaneous coronary intervention. The trial also found that fondaparinux was associated with fewer major bleeding events compared to enoxaparin.